Skip to main content
Premium Trial:

Request an Annual Quote

Fosun Diagnostics to Market Miacom's Molecular Beacon Assays in Asia

NEW YORK (GenomeWeb) — Miacom Diagnostics and Fosun Diagnostics said today that they have partnered to market Miacom's molecular beacon-based diagnostic assays to the Chinese and broader Asian markets.

Under the agreement, Shanghai-based Fosun, the diagnostic division of Shanghai Fosun Pharmaceutical, will market Dusseldorf, Germany-based Miacom's proprietary multiplex assays for the detection of sepsis- and pneumonia-related pathogens.

Miacom's assays enable the identification of a wide variety of pathogens using molecular beacons and fluorescence in situ hybridization, according to its website. The company also said its tests use a proprietary sample-handling method, and that its assays can identify and differentiate various bacteria in 30 minutes.

Having Fosun Diagnostics as a partner "makes widespread distribution of our products in the Asian market feasible," Miacom CEO Mirko Stange said in a statement. "We believe that this partnership will further strengthen our position in other markets, as well."

Fosun Diagnostics is planning to build a US Food and Drug Administration-compliant, large-scale production facility that will dramatically reduce the production costs of Miacom's products and help the company move into the European and American markets, Miacom said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.